ClinicalTrials.gg
CompletedNCT04008979Updated Jul 5, 2019

Pharmacokinetic and Pharmacodynamic Assessment of a Novel, Pharmaceutical Lipid-Aspirin Complex

A Phase 1 interventional study of Aspirin in Bioequivalence, sponsored by PLx Pharma. Completed. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-05.

Sponsored by PLx Pharma · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2008, 18 years 5 months ago, and no results have been posted to the registry.
  • Registered 11 years 4 months after the study started (first participant enrolled Feb 2008, registered Jul 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

Prospective, Randomized, Crossover, Bioequivalence study

Read the detailed description

Active-control crossover study randomizing 32 healthy volunteers to receive one of two dose levels, 325 mg or 650 mg, of either PL-ASA or immediate release aspirin within a two week washout period between treatments. The primary objectives are to assess PK and PD bioequivalence and safety over a twenty four hour period for PL-ASA and immediate release aspirin at 325 mg and 650 mg dose strengths.

02

Conditions studied

  • Bioequivalence
03

In context

Lead sponsor

PLx Pharma is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • If female and of , subject has a negative pregnancy test and is not nursing.
  • If female and of childbearing potential, subject is using adequate for the duration of the study.
  • Subject is able to understand and comply with study procedures.
  • Subject is a non-smoker.
  • Subject consumes no more than 1 alcoholic drink per day.
  • Subject agrees to refrain from alcohol consumption for 48 hours prior to each drug administration and 48 hours after each drug administration.
  • Subject is able and willing to provide written prior to any study procedures being performed.

Exclusion criteria

Exclusion Criteria:

  • Subject has abnormal screening/baseline laboratory parameters deemed to be by the Investigator.
  • Subject has taken any prescription medications other than hormone replacement therapy or thyroid replacement hormones within 3 days prior to drug administration.
  • Subject has taken any of the following medications within 2 weeks prior to study entry:

    • NSAIDs or other medications for pain, including aspirin or aspirin containing products and acetaminophen (see Appendix B of protocol in Appendix 16.1.1)
    • Proton pump inhibitors, including Prilosec®, Prevacid®, Aciphex®, Protonix®, or Nexium®
    • H-2 blockers, including Tagamet®, Zantac®, Axid®, or Pepcid®
    • Any antiplatelet agent, including Plavix®, Ticlid®, Pletal®, ReoPro®, Integrilin®, Aggrastat®, or Persantine®
    • Any anti-coagulant, including Coumadin®, Acenocoumarol, Phenprocoumon, Phenindione, Heparin, Exanta®, Argatroban, Lepirudin, Hirudin or Bivalirudin
  • Subject has used an agent within the past 30 days.
  • Subject has or to aspirin, ibuprofen, or other NSAID.
  • Subject has sensitivity to lecithin.
  • Subject has a history of gastrointestinal problems including ulcers, frequent indigestion, or heartburn.
  • Subject has a history of stroke, myocardial infarction, or congestive heart failure.
  • Subject has a history of asthma, other bronchospastic activity, nasal polyps, or angioedema other than resolved childhood asthma.
  • Subject has a history of kidney or liver disease.
  • Subject has a history of thrombocytopenia, neutropenia, or bleeding disorder.
  • Subject has a history of coronary arterial bypass.
  • Subject has a history of non-trauma related hemorrhage.
  • Subject has a history of chronic hypertension.
  • Subject is currently enrolled in another investigational trial.
  • Subject's are unresponsive to arachidonic acid
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    PL-ASA 325 mg

    Novel aspirin formulation being tested

    Drug: Aspirin

  • Active comparator
    IR 325 mg

    Immediate release aspirin

    Drug: Aspirin

  • Experimental
    PL-ASA-650

    Novel aspirin formulation being tested

    Drug: Aspirin

  • Active comparator
    IR 650

    Immediate release aspirin

    Drug: Aspirin

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence of PL-ASA and Immediate Release Aspirin AUC0-T

    Assess for bioequivalence at 325 mg and 650 mg dose levels AUC0-T of the metabolite salicylic acid

    Time frame: twenty four hours

  2. Bioequivalence of PL-ASA and Immediate Release Aspirin AUC0-∞

    Assess for bioequivalence at 325 mg and 650 mg dose levels AUC0-∞ of the metabolite salicylic acid

    Time frame: 24 hours

  3. Bioequivalence of PL-ASA and Immediate Release Aspirin CMAX

    Assess for bioequivalence at 325 mg and 650 mg dose levels CMAX of the metabolite salicylic acid

    Time frame: 24 hours

  4. Bioequivalence of PL-ASA and Immediate Release Aspirin TMAX

    Assess for bioequivalence at 325 mg and 650 mg dose levels TMAX of the metabolite salicylic acid

    Time frame: 24 hours

  5. Bioequivalence of PL-ASA and Immediate Release Aspirin AUC0-24

    Assess for bioequivalence at 325 mg and 650 mg dose levels AUC0-24 of the percent inhibition of serum Thromboxane B2

    Time frame: 24 hours

  6. Bioequivalence of PL-ASA and Immediate Release Aspirin TMAX STB2

    Assess for bioequivalence at 325 mg and 650 mg dose levels TMAX of the percent inhibition of serum Thromboxane B2

    Time frame: 24 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Angiolillo DJ, Bhatt DL, Lanza F, Cryer B, Dong JF, Jeske W, Zimmerman RR, von Chong E, Prats J, Deliargyris EN, Marathi U. Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study. J Thromb Thrombolysis. 2019 Nov;48(4):554-562. doi: 10.1007/s11239-019-01933-7. PubMed 31420787 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2008 to primary completion in Jun 2008, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2019
First posted
Jul 5, 2019
StartActual
Feb 11, 2008
Primary completionActual
Jun 10, 2008
CompletionActual
Jun 10, 2008
Last update
Jul 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04008979
Lead sponsor
PLx Pharma
Responsible party
Sponsor
First posted
Jul 5, 2019
Start date
Feb 11, 2008
Primary completion
Jun 10, 2008
Completion
Jun 10, 2008
Last update
Jul 5, 2019

Study contacts

Upendra Marathi, PhD
study director · PLx Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion